Lyra Therapeutics, Inc. (LYRA)
2025-06-30 | 2025-03-31 | 2024-09-30 | ||
|---|---|---|---|---|
| Collaboration revenue | 183 | 183 | 195 | |
| Restructuring and other related charges | 398 | 885 | - | |
| Research and development | 5,110 | 4,876 | - | |
| Impairment of property and equipment | - | - | - | |
| General and administrative | 3,501 | 3,263 | - | |
| Impairment of right-of-use assets | - | - | - | |
| Total operating expenses | 9,009 | 9,024 | 12,637 | |
| Loss from operations | -8,826 | -8,841 | -12,442 | |
| Other income | 981 | - | - | |
| Interest income | 410 | 298 | 576 | |
| Total other income | 1,391 | 298 | 576 | |
| Loss before income tax expense | -7,435 | -8,543 | -11,866 | |
| Income tax expense | 2 | 4 | 7 | |
| Net loss | -7,437 | -8,547 | -11,873 | |
| Unrealized holding loss on short-term investments, net of tax | - | - | 24 | |
| Comprehensive loss | -7,437 | -8,547 | -11,849 | |
| Earnings per share, basic, total | -5.51 | -0.13 | -0.18 | |
| Earnings per share, diluted, total | -5.51 | -0.13 | -0.18 | |
| Weighted average number of shares outstanding, basic, total | 1,348,630 | 65,757,860 | 65,456,735 | |
| Weighted average number of shares outstanding, diluted, total | 1,348,630 | 65,757,860 | 65,456,735 | |